- Home
- BIIB vs VTR Comparison
BIIB vs VTR Comparison
Compare BIIB & VTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- VTR
- Stock Information
- Founded
- BIIB 1978
- VTR 1983
- Country
- BIIB United States
- VTR United States
- Employees
- BIIB N/A
- VTR N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- VTR Real Estate Investment Trusts
- Sector
- BIIB Health Care
- VTR Real Estate
- Exchange
- BIIB Nasdaq
- VTR Nasdaq
- Market Cap
- BIIB 25.1B
- VTR 27.3B
- IPO Year
- BIIB 1991
- VTR 1998
- Fundamental
- Price
- BIIB $159.26
- VTR $62.13
- Analyst Decision
- BIIB Buy
- VTR Buy
- Analyst Count
- BIIB 25
- VTR 10
- Target Price
- BIIB $258.57
- VTR $61.60
- AVG Volume (30 Days)
- BIIB 1.6M
- VTR 2.5M
- Earning Date
- BIIB 10-30-2024
- VTR 10-30-2024
- Dividend Yield
- BIIB N/A
- VTR 2.89%
- EPS Growth
- BIIB 10.05
- VTR N/A
- EPS
- BIIB 11.06
- VTR N/A
- Revenue
- BIIB $9,607,500,000.00
- VTR $4,797,115,000.00
- Revenue This Year
- BIIB N/A
- VTR N/A
- Revenue Next Year
- BIIB N/A
- VTR $7.07
- P/E Ratio
- BIIB $14.41
- VTR N/A
- Revenue Growth
- BIIB N/A
- VTR 10.05
- 52 Week Low
- BIIB $153.62
- VTR $41.45
- 52 Week High
- BIIB $268.30
- VTR $67.61
- Technical
- Relative Strength Index (RSI)
- BIIB 35.47
- VTR 39.49
- Support Level
- BIIB $158.44
- VTR $61.73
- Resistance Level
- BIIB $165.29
- VTR $65.24
- Average True Range (ATR)
- BIIB 3.42
- VTR 0.98
- MACD
- BIIB 1.04
- VTR -0.23
- Stochastic Oscillator
- BIIB 44.34
- VTR 15.03
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About VTR Ventas Inc.
Ventas owns a diversified healthcare portfolio of over 1,300 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.